Suppr超能文献

风险效益评估的概念。对一种药物的简单价值分析?

Concepts in risk-benefit assessment. A simple merit analysis of a medicine?

作者信息

Edwards R, Wiholm B E, Martinez C

机构信息

WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden.

出版信息

Drug Saf. 1996 Jul;15(1):1-7. doi: 10.2165/00002018-199615010-00001.

Abstract

The term 'benefit-risk ratio' is often used as a general term linked to the use of a medicine. To balance risk and benefit is, however, a very complex exercise. For most medicines the benefits are limited to a few indications and for an individual patient there is usually only a single benefit sought but the potential risks are multiple. Perceptions of risks versus benefits are influenced to a great extent by the context in which they occur. Thus, perception of risk may be different to actual risk. In the end in any given situation, the acceptable risk-to-benefit balance is an individual judgement on the part of the patient or the prescriber. For newer medicines, where there is likely to be limited experience, conservative estimates of the overall merit seem preferable so that the prescriber will use the drug critically. Subsequently, re-evaluation of the risk-to-benefit balance is necessary as greater knowledge of efficacy and adverse effects is acquired. It is possible to provide a general 'principle of threes' structure for a merit assessment based upon the concepts of seriousness, duration and incidence as related to disease indication, disease amelioration by a medicine, and the adverse effects ascribed to the medicine. This allows a rapid first comparison of medicines for a given indication. In using this general conceptual model in a transparent fashion for a given hypothesis and context, it is possible to identify the essential data used and assumptions involved that make up a merit statement. The quality and value, particularly of risk data, is problematic. Risk perception is an issue that needs to be clearly identified alongside a merit analysis. A simple merit assessment should pave the way for more focused studies.

摘要

“获益-风险比”这一术语常被用作与药物使用相关的通用术语。然而,平衡风险与获益是一项非常复杂的工作。对于大多数药物而言,其获益仅限于少数适应证,而且对于个体患者来说,通常寻求的获益只有一项,但潜在风险却有多项。对风险与获益的认知在很大程度上受其发生背景的影响。因此,对风险的认知可能与实际风险不同。最终,在任何特定情况下,可接受的风险-获益平衡是患者或开处方者的个人判断。对于经验可能有限的新药,对总体价值进行保守估计似乎更为可取,这样开处方者会谨慎使用该药物。随后,随着对疗效和不良反应有了更多了解,有必要重新评估风险-获益平衡。基于与疾病适应证、药物对疾病的改善以及归因于该药物的不良反应相关的严重性、持续时间和发生率的概念,有可能为价值评估提供一个通用的“三三原则”结构。这能对给定适应证的药物进行快速的初步比较。以透明的方式针对给定的假设和背景使用这个通用概念模型时,有可能识别构成价值陈述所使用的基本数据和涉及的假设。风险数据的质量和价值,尤其是其质量和价值,存在问题。在进行价值分析时,风险认知是一个需要明确识别的问题。简单的价值评估应为更有针对性的研究铺平道路。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验